GeneDx enters $75M at-the-market equity offering agreement with TD Securities

GeneDx Holdings Corp.

Company may sell up to $75M of Class A common stock through TD Cowen as agent.
TD Cowen will receive up to 3.0% selling commission on gross proceeds.
ATM offering terminates upon sale of all shares or termination of agreement.
Offering made under existing shelf registration statement (File No. 333-267112).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

GeneDx Holdings Corp. entered into Sales Agreement with TD Securities (USA) LLC valued at up to $75.0 million (effective 2024-04-29).

Action: entry
Agreement: atm program
Counterparty: TD Securities (USA) LLC
Value: up to $75.0 million
Effective: 2024-04-29

Exact text from the filing

On April 29, 2024, GeneDx Holdings Corp. (the “Company”), entered into a sales agreement (the “Sales Agreement”) with TD Securities (USA) LLC, as sales agent and/or principal (“TD Cowen”), pursuant to which the Company may offer and sell, from time to time to or through TD Cowen, shares of the Company’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), having an aggregate offering price of up to $75.0 million (the “Shares”).

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

GeneDx Holdings Corp. filing history →

Source: SEC EDGAR

accession 0001818331-24-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.